AngioDynamics' (ANGO) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of AngioDynamics (NASDAQ:ANGO - Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $14.00 price target on the medical instruments supplier's stock.

Separately, Canaccord Genuity Group cut their price objective on AngioDynamics from $13.00 to $12.00 and set a buy rating for the company in a report on Friday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $12.00.

AngioDynamics Stock Performance

AngioDynamics stock traded down $0.27 during mid-day trading on Friday, reaching $6.10. The company's stock had a trading volume of 1,310,668 shares, compared to its average volume of 522,570. AngioDynamics has a 12 month low of $5.26 and a 12 month high of $8.25. The business's 50 day simple moving average is $7.48 and its 200 day simple moving average is $6.62. The company has a market capitalization of $244.34 million, a price-to-earnings ratio of -1.26 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The company had revenue of $67.50 million during the quarter, compared to analysts' expectations of $67.93 million. During the same quarter last year, the company earned ($0.12) EPS. AngioDynamics's revenue for the quarter was down 14.2% compared to the same quarter last year. As a group, sell-side analysts expect that AngioDynamics will post -0.41 EPS for the current year.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently added to or reduced their stakes in ANGO. SG Americas Securities LLC bought a new position in shares of AngioDynamics in the third quarter valued at about $103,000. Quarry LP raised its holdings in AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 2,594 shares during the period. Systematic Financial Management LP lifted its position in AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock worth $12,763,000 after acquiring an additional 162,972 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of AngioDynamics during the second quarter worth approximately $80,000. Finally, Millennium Management LLC grew its position in shares of AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock valued at $10,850,000 after purchasing an additional 529,861 shares during the last quarter. Institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.